CARISMA THERAPEUTICS INC (CARM) Stock Price, Quote, News and Overview
NASDAQ:CARM - Nasdaq - US14216R1014 - Common Stock - Currency: USD
CARM Quote, Performance and Key Statistics
0.401
-0.01 (-2.2%)
The current stock price of CARM is 0.401 USD. In the past month the price decreased by -19.64%. In the past year, price decreased by -84.52%.
CARM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.66 | 369.39B | ||
| AMGN | AMGEN INC | 15.54 | 165.43B | ||
| GILD | GILEAD SCIENCES INC | 24.8 | 142.43B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1654.45 | 123.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.31 | 76.39B | ||
| ARGX | ARGENX SE - ADR | 242.12 | 37.96B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.83B | ||
| ONC | BEIGENE LTD-ADR | N/A | 29.00B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.07B | ||
| NTRA | NATERA INC | N/A | 20.54B | ||
| BIIB | BIOGEN INC | 8.53 | 20.47B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.26B |
Related stock screener links
About CARM
Company Profile
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Philadelphia, Pennsylvania and currently employs 107 full-time employees. The company went IPO on 2014-02-06. The company is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Company Info
CARISMA THERAPEUTICS INC
3025 Market Street Ste 140
PHILADELPHIA PENNSYLVANIA US
Employees: 107
Company Website: https://sesenbio.com/
Investor Relations: https://ir.carismatx.com/
Phone: 16174448550
CARISMA THERAPEUTICS INC / CARM FAQ
What is the stock price of CARISMA THERAPEUTICS INC today?
The current stock price of CARM is 0.401 USD. The price decreased by -2.2% in the last trading session.
What is the ticker symbol for CARISMA THERAPEUTICS INC stock?
The exchange symbol of CARISMA THERAPEUTICS INC is CARM and it is listed on the Nasdaq exchange.
On which exchange is CARM stock listed?
CARM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CARISMA THERAPEUTICS INC stock?
10 analysts have analysed CARM and the average price target is 6.63 USD. This implies a price increase of 1553.37% is expected in the next year compared to the current price of 0.401. Check the CARISMA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CARISMA THERAPEUTICS INC worth?
CARISMA THERAPEUTICS INC (CARM) has a market capitalization of 16.74M USD. This makes CARM a Nano Cap stock.
How many employees does CARISMA THERAPEUTICS INC have?
CARISMA THERAPEUTICS INC (CARM) currently has 107 employees.
What are the support and resistance levels for CARISMA THERAPEUTICS INC (CARM) stock?
CARISMA THERAPEUTICS INC (CARM) has a resistance level at 0.43. Check the full technical report for a detailed analysis of CARM support and resistance levels.
Is CARISMA THERAPEUTICS INC (CARM) expected to grow?
The Revenue of CARISMA THERAPEUTICS INC (CARM) is expected to grow by 58.08% in the next year. Check the estimates tab for more information on the CARM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CARISMA THERAPEUTICS INC (CARM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CARM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CARM, evaluating the profitability, health, valuation and growth aspects
- CARISMA THERAPEUTICS INC (CARM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CARISMA THERAPEUTICS INC (CARM) Sales and EPS estimates to see what analysts future expectations are.
- CARISMA THERAPEUTICS INC (CARM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CARISMA THERAPEUTICS INC (CARM) Insider and Institutional Ownership to learn about the owners and their transactions.
- CARISMA THERAPEUTICS INC (CARM) Stock Chart to make your own analysis
- CARISMA THERAPEUTICS INC (CARM) Latest news and press-releases to stay up to date.
Does CARISMA THERAPEUTICS INC (CARM) stock pay dividends?
CARM does not pay a dividend.
When does CARISMA THERAPEUTICS INC (CARM) report earnings?
CARISMA THERAPEUTICS INC (CARM) will report earnings on 2025-03-31, after the market close.
What is the Price/Earnings (PE) ratio of CARISMA THERAPEUTICS INC (CARM)?
CARISMA THERAPEUTICS INC (CARM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.56).
What is the Short Interest ratio of CARISMA THERAPEUTICS INC (CARM) stock?
The outstanding short interest for CARISMA THERAPEUTICS INC (CARM) is 2.4% of its float. Check the ownership tab for more information on the CARM short interest.
CARM Technical Analysis
CARM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CARM. Both the profitability and financial health of CARM have multiple concerns.
CARM Financial Highlights
Over the last trailing twelve months CARM reported a non-GAAP Earnings per Share(EPS) of -1.56. The EPS increased by 58.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -151.7% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CARM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to CARM. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 64.73% and a revenue growth 58.08% for CARM